INDV · CIK 1625297
What Indivior plc told the SEC could break it.
Indivior's risks pivot on concentration in a single product and a single plant. One product, SUBLOCADE, was 69% of net revenue in 2025 (up from 64%), with nearly all the rest from other buprenorphine sublingual products, so any supply, competitive or reimbursement shock to SUBLOCADE would dominate results. The buprenorphine active ingredient for that entire franchise is made at one internal facility — the Fine Chemical Plant in Hull, U.K. — which produces all of its current requirements, so a disruption there would hit virtually every product. Its supply chain has a second pinch point: it buys the naloxone HCl API for SUBOXONE mainly from a single supplier, where switching would take significant time and regulatory approval, and it imports raw materials and API exposed to tariffs it has limited ability to pass through under IRA price-increase limits.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Geographic concentration
- Single API plant — Fine Chemical Plant, Hull, U.K. (all buprenorphine API)high
Indivior manufactures the primary buprenorphine API for its entire franchise — SUBLOCADE, SUBOXONE Film, SUBOXONE/SUBUTEX Tablets — at a single internal facility, the Fine Chemical Plant in Hull, U.K., which produces all of its current buprenorphine requirements; any disruption there would hit virtually all products.
“The primary API used in our buprenorphine products are manufactured at our Fine Chemical Plant ("FCP") located in Hull, United Kingdom.”
SEC filing →As of 2026
Other disclosures
- Single-product concentration — SUBLOCADE = 69% of net revenuemedium
Indivior's revenue is concentrated in one product: SUBLOCADE accounted for 69% of net revenue in 2025 (up from 64% in 2024), with nearly all remaining revenue from other buprenorphine sublingual products — so any supply, competitive (e.g. Camurus/Braeburn BRIXADI) or reimbursement shock to SUBLOCADE would dominate results.
“SUBLOCADE accounted for 69% and 64% of our net revenue in 2025 and 2024, respectively.”
SEC filing →As of 2026
Regulatory & policy
- Tariffs on imported API & raw materials (U.K./EU/Australia/Japan/Philippines)medium
Indivior imports raw materials, components and API from the U.K., EU, Australia, Japan and the Philippines, with its main buprenorphine API coming from its own U.K. plant; tariffs apply to both SUBLOCADE and SUBOXONE Film, and the company has limited ability to avoid them or pass them through given IRA price-increase limits.
“We import certain raw materials, components, and API from the U.K., EU, Australia, Japan, and the Philippines. Tariffs apply to both SUBLOCADE and SUBOXONE Film but with moderate impact based on the latest tariffs, especially since the main contributors (APIs) originate from our manufacturing plant in the U.K.”
Sole-source dependency
- Single supplier of naloxone HCl API (SUBOXONE Tablet & Film)medium
Indivior buys the naloxone HCl API for SUBOXONE Tablet and SUBOXONE Film mainly from a single supplier; while alternatives exist, switching would require significant time to qualify and obtain regulatory approval, so a supplier disruption could interrupt SUBOXONE production.
“We procure the naloxone HCl active pharmaceutical ingredient mainly from a single supplier for both SUBOXONE Tablet and SUBOXONE Film. It is readily available from other suppliers (however it would require significant time to qualify and obtain regulatory approval to change suppliers).”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
“SUBOXONE Film is manufactured under an exclusive license and supply agreement with Aquestive Therapeutics.”
Cited →Reckitt Benckiser Group plc (RB)
“We contract with RB to manufacture SUBOXONE and SUBUTEX Tablets.”
Cited →“Indivior accounted for approximately 73% and 62% of our revenues for 2025 and 2024, respectively, and we believe in the future will continue to account for a substantial part of our revenues.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch